我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

替米沙坦对高血压病患者纤溶功能的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第6期
页码:
658-660
栏目:
临床研究
出版日期:
2007-12-20

文章信息/Info

Title:
Changes of fibrinolytic function in hypertensive patients after Telmisartan interference
作者:
马岩; 徐秀英
首都医科大学附属北京天坛医院心内科，北京 100050
Author(s):
MA Yan;  XU Xiu-ying
Department of Cardiology, Beijing Tiantan Hospital, Affilicate of Medical Capital University, Beijing 100050，China
关键词:
高血压; 原发性; 替米沙坦; 纤溶酶原活化物抑制剂-1; 组织型纤溶酶原活化物
Keywords:
hypertension; primary;  Telmisartan;  plasminogen activator inhibiter-1;  tissuetype plasminogen activator
分类号:
R544.1
DOI:
-
文献标识码:
A
摘要:
目的 了解替米沙坦对高血压患者纤溶功能的影响。方法 选择轻-中度原发性高血压患者64例，给予替米沙坦80 mg/d， 8周，分别于药物干预前后测定高血压病患者的血压、血浆纤溶酶原活化物抑制剂1（PAI1）和组织型纤溶酶原活化物（tPA）水平。比较药物干预前后的血压、血浆PAI1、tPA水平，以及不同降压效果组间的血浆PAI1、tPA水平。结果 ①高血压病患者替米沙坦干预后，收缩压和舒张压均显著下降（P<0.01）。②替米沙坦干预后，血浆PAI1含量显著下降［（53.±23）vs （24.±5.）μg/L，P<0.01］。tPA/PAI1比值经药物干预后，显著上升［（0.25±0.13） vs (0.45±0.20),P<0.01］。③替米沙坦干预后，不同降压效果组间PAI1含量及tPA/ PAI1比值的变化有显著性差异（P<0.01）。结论 替米沙坦可以改善高血压病患者的纤溶功能且对高血压病患者纤溶功能的影响是独立于降压作用之外的。
Abstract:
AIM To explore the effect of Telmisartan on fibrinolytic function in hypertensive patients. METHODS Sixtyfour mildtomoderate essential hypertensive patients were given Telmisartan 80 mg/day for eight weeks. The plasma level of PAI1 and tPA were measured by ELISA (enzymelinked immunosorbent assay) before and after Telmisartan interference. RESULTS ①After 8 weeks′ Telmisartan interference, systolic pressure and diastolic pressure significantly decreased, (P<0.01). ②PAI1 level in hypertensive patients significantly decreased（53±23 vs 24±5）μg/L (P<0.01). The ratio of tPA/PAI1 in hypertensive patients significantly increased （0.25±0.13 vs 0.45±0.20，P<0.01）. ③The changes of PAI1 level and tPA/PAI1 ratio after Telmisartan interference were significantly different in different subgroups. CONCLUSION These results indicate that Telmisartan improves the fibrinolytic function in hypertensive patients but not by lowering the blood pressure.

参考文献/References

［1］ Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV［J］. J Clin Invest, 1995, 96(5): 2515-2520.

［2］ Mehta JL,Li DY,Yang H ,et al.Angiotensin II and IV stimuiate expression and release of piasminogen activator inhibitor1 in cultured human coronary awtery endothelial Cells ［J］. J Cardiovasc Pharmacol,2002,39(6):789-794.

［3］ Weisberg AD,Albornoz F,Griffin JP, et al. Pharmaclilgical inhibition and genetic deficiency of plasminogen activator inhibitorl attenuayes angiotensin II/saltInduced aortic remodeling［J］. Arterioscler Thromb Vasc Biol， 2005,25(2):365-371.

4］ Mugellini A, Preti P, Zoppi A,et al.Effect of delaprilmanidipine combination vs irbesartanhydrochlorothizide combination on fibrinolytic function in hypertensive patienrs with type II diabetes mellitus［J］. J Hum Hypertens, 2004,18(10):687-691.

［5］ Pretorius M,Luther JM, Murphey LJ, et al. Angiotensinconverting enzyme inhibition increases basal vascular tissue plasminogen activator release inwomen but not in men［J］. Arterioscler Thromb Vasc Biol， 2005,25(11):2435-2440.

备注/Memo

备注/Memo:
收稿日期：2006-08-09.通讯作者：徐秀英，主任医师，主要从事心血管病诊治研究 Email:xxyddy@yahoo.com.cn 作者简介：马岩，硕士，主治医师 Email:sun741004@ yahoo.com.cn
更新日期/Last Update: